In line with these findings, we suggest that steroids might also influence the human CB in such a way that not the production, but the composition of the aqueous humor alters. This may ultimately affect the molecular interactions with the TM and increase the outflow resistance. Besides the endocrinological signaling pathways, we also found several pathways of metabolism and disease. These molecular mechanisms included metabolism of glucose, lipid and vitamins and the disease diabetes mellitus. The pathways and involved genes concerning glucose metabolism are interesting in light of the function of the aqueous humor. Ovarian cancer has a higher fatality-to-case ratio than any other gynecologic malignancy, since it tends to be complex by symptoms and misdiagnosed than other diseases, which results in the vast majority of patients with ovarian cancer being diagnosed in advanced metastatic stages. The PF-04217903 msds 5-year survival rate of patients with early stage cancer ranges from 50– 95%, but only approximately 20% of all reported cases are caught in the early stages; the 5-year survival rate is approximately 11% when detected in the advanced stages. Therefore, many efforts have been focused on the identification of diagnostic biomarkers for early detection of ovarian cancer. Because the disease exhibits metabolic changes due to the presence of the tumor and potential genetic variations that affect blood chemistry during the course of tumor progression. The cancer antigen 125 assay is the most used clinical biomarker for ovarian cancer. However, CA125 has proven to be a poor diagnostic tumor biomarker because it lacks specificity and sensitivity for early ovarian cancer. It is elevated above reference levels in only 50% of clinically detectable early stage disease, and is not infrequently elevated in patients with benign ovarian diseases. In addition, CA125 levels are falsely elevated in pregnant women and women with detectable intraperitoneal pathologies. Therefore, attempts have been made to combine or replace CA125 with other markers, and investigators have evaluated the ability of some established markers to improve the identification and prognosis of ovarian cancer, thus indicating that the addition of one or several markers to CA125 would improve diagnostic and prognostic performance if sensitivity was improved without a loss in specificity. However, because the measurement of serum concentration of each putative biomarker with individual ELISAs requires considerable time, cost, and sample volumes, new methods or technologies for multiplexing must be developed. The Luminex bead-based system is a automated high-throughput assay platform that provides multiplexing in a solution phase, resulting in it being particularly flexible and nondestructive for protein analysis. The use of detection antibodies labeled with biotin and streptavidin-R-phycoerythrin allows quantification of antigen-antibody reactions that occur on the microsphere surface through the measurement of the relative fluorescence intensity. Therefore, the system is capable of measuring up to 100 analytes simultaneously in a small sample volume, indicating multivariate methods that use a panel of biomarkers to predict specific clinical end points of interest. In this study, we attempted to measure three serum biomarkers of ovarian cancer, CA125, transthyretin, and apolipoprotein A1, using a multiplex bead-based immunoassay system, and evaluated the combined effect of the three biomarkers for the diagnosis of ovarian cancer compared with those of the individual markers alone.